Samjin looks to newly emerging appetite stimulant market

Samjin Pharm said the annual revenue of its OTC appetite stimulant drug “Trestan” will reach 10 billion won, thanks much to increasing market demand.

“The domestic market for appetite-stimulating pharmaceuticals, which are primarily designed for patients who are underweight as a result of cancer treatments, chronic illnesses, and for the elderly, will be spotlighted for the years to come,” a...